Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

<h4>Background</h4>A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was...

Full description

Saved in:
Bibliographic Details
Main Authors: Jane J Kim, Kate T Simms, James Killen, Megan A Smith, Emily A Burger, Stephen Sy, Catherine Regan, Karen Canfell
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2021
Subjects:
Medicine
R
Online Access:https://doaj.org/article/c7a9a728c2a34564b00d467c9944ca6f
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items